Sponsored ADR (NASDAQ:PPBT – Free Report) – Investment analysts at HC Wainwright lowered their Q3 2026 EPS estimates for Purple Biotech in a research note issued on Friday, August 7th. HC Wainwright also issued estimates for Purple Biotech’s Q4 2026 earnings at ($3.00) EPS, FY2026 earnings at ($5.73) EPS, FY2027 earnings at ($1.01) EPS, FY2028 earnings at ($0.51) EPS, FY2029 earnings at ($0.37) EPS and FY2030 earnings at ($0.12) EPS. Zacks Research upgraded Purple Biotech from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Hedge Funds Weigh In On Purple BiotechA hedge fund recently bought a new stake in Purple Biotech stock. SmartHarvest Portfolios LLC owned about 0.37% of Purple Biotech as of its most recent filing with the SEC.